Djaman Joseph Allico, Olefongo Dagnogo, Ako Aristide Berenger, Roman Jocelyne, Ngane Vincent Foumane, Basco Leonardo K, Tahar Rachida
Département de Parasitologie-Mycologie, Institut Pasteur de Côte d'Ivoire, Abidjan, Côte d'Ivoire.
Laboratoire de Pharmacodynamie Biochimique, UFR Biosciences, Université Félix Houphouët-Boigny, Abidjan, Côte d'Ivoire.
Am J Trop Med Hyg. 2017 Jul;97(1):222-224. doi: 10.4269/ajtmh.16-0889.
Artemisinin-resistant malaria has not been reported from Africa, but resistance can possibly spread from Asia or arise independently in Africa. The emergence of artemisinin resistance in Africa can be monitored by molecular assay of Kelch 13 (K13) propeller sequences. A total of 251 archived DNA samples of isolates collected in 2002, 2003, and 2006 in Yaounde, Cameroon, and 47 samples collected in 2006 and 2013 in Abidjan, Côte d'Ivoire, were analyzed for K13-propeller sequence polymorphism. Only one isolate carried a mutant K13-propeller allele (E602D). None of the isolates carried the key mutant alleles (Y493H, R539T, I543T, and C580Y) associated with artemisinin resistance in Cambodia. The presence of the mutant allele was not correlated with in vitro response to dihydroartemisinin determined by the classical hypoxanthine incorporation assay. There was no evidence of K13 mutations associated with artemisinin resistance before and soon after the introduction of artemisinin-based combination therapies in Cameroon and Côte d'Ivoire.
非洲尚未报告出现对青蒿素耐药的疟疾,但耐药性可能会从亚洲传播过来,或者在非洲独立出现。可通过对凯尔奇13(K13)螺旋桨序列进行分子检测来监测非洲青蒿素耐药性的出现情况。对2002年、2003年和2006年在喀麦隆雅温得采集的251份存档分离株DNA样本,以及2006年和2013年在科特迪瓦阿比让采集的47份样本进行了K13螺旋桨序列多态性分析。仅1株分离株携带K13螺旋桨突变等位基因(E602D)。没有任何分离株携带与柬埔寨青蒿素耐药性相关的关键突变等位基因(Y493H、R539T、I543T和C580Y)。突变等位基因的存在与通过经典次黄嘌呤掺入试验测定的对双氢青蒿素的体外反应无关。在喀麦隆和科特迪瓦引入以青蒿素为基础的联合疗法之前及之后不久,均没有证据表明存在与青蒿素耐药性相关的K13突变。